凯莱英(002821) - 2024 Q3 - 季度财报

Financial Performance - In Q3 2024, Asymchem Labs reported revenue of CNY 1.44 billion, a decrease of 18.09% year-over-year, and a total revenue of CNY 4.14 billion for the first three quarters, down 35.14% year-over-year[3]. - The net profit attributable to shareholders was CNY 211.19 million in Q3 2024, a decline of 59.68% year-over-year, with a total net profit of CNY 710.33 million for the first three quarters, down 67.86% year-over-year[3]. - Total revenue for Q3 2024 was approximately RMB 4.14 billion, a decrease of 35.14% compared to RMB 6.38 billion in Q3 2023, primarily due to the absence of large orders delivered in the same period last year[7]. - Operating profit for Q3 2024 was approximately RMB 761.46 million, down 69.41% from RMB 2.49 billion in Q3 2023, mainly due to the decrease in revenue[7]. - The net profit for Q3 2024 was approximately ¥700.18 million, a significant decrease of 68.2% compared to ¥2.20 billion in Q3 2023[18]. - Basic and diluted earnings per share for Q3 2024 were both ¥2.01, down from ¥6.10 in Q3 2023[19]. - The total comprehensive income for Q3 2024 was approximately ¥698.37 million, a decrease of 68.4% from ¥2.21 billion in Q3 2023[19]. Profitability and Margins - The company achieved a gross profit margin of 43.60% for the first three quarters, with a decrease of 1.02 percentage points year-over-year, while the gross margin for small molecule business was 48.89%, an increase of 1.19 percentage points year-over-year[4]. - The small molecule business generated revenue of CNY 3.39 billion in the first three quarters, with a year-over-year growth of 7.71% after excluding large orders[4]. - Operating revenue for the current period was 4.14 billion yuan, down 35.1% from 6.38 billion yuan in the previous period[17]. - Total operating costs decreased from 4.05 billion yuan to 3.42 billion yuan, a decline of about 15.6%[17]. Cash Flow and Investments - The company's cash flow from operating activities for the first three quarters was CNY 1.05 billion, down 63.24% year-over-year[3]. - Cash inflow from operating activities was ¥4.98 billion, down 28.3% from ¥6.94 billion in the previous year[20]. - The total cash outflow from investing activities was ¥9,830,165,531.45, down from ¥20,999,540,521.49 in the same period last year[21]. - The cash inflow from investment activities was ¥8,739,043,535.13, down from ¥20,104,491,861.56 in Q3 2023[21]. - The company invested approximately RMB 240 million in industry funds, representing a 390.99% increase compared to RMB 48.88 million in the same period last year[7]. Assets and Liabilities - The total assets of Asymchem at the end of Q3 2024 were CNY 18.70 billion, a decrease of 5.41% compared to the end of the previous year[3]. - Total current assets decreased from 12.35 billion yuan to 10.61 billion yuan, a reduction of approximately 14.1%[15]. - Cash and cash equivalents decreased from 7.11 billion yuan to 5.20 billion yuan, a decline of about 26.7%[14]. - Total liabilities decreased from 2.26 billion yuan to 2.06 billion yuan, a reduction of approximately 9%[16]. - The company's total equity decreased from 17.51 billion yuan to 16.63 billion yuan, a reduction of about 5%[16]. Shareholder Information - The top shareholder, ASYMCHEM LABORATORIES, holds 31.31% of the shares, totaling 115,133,168 shares[8]. - The total number of ordinary shareholders at the end of the reporting period was 53,290[8]. - The company repurchased a total of 12,300,701 shares, accounting for 3.60% of the total A-share capital, with a total expenditure of approximately RMB 999.64 million[12]. - The company plans to continue its stock repurchase program with a total fund not less than RMB 600 million and not exceeding RMB 1.2 billion[12]. - The company plans to increase its A-share holdings by at least 20 million yuan, reflecting confidence in its future development and value recognition by key personnel[13]. Research and Development - Research and development expenses for the current period were 484.14 million yuan, compared to 513.11 million yuan in the previous period, a decrease of approximately 5.7%[17]. - Asymchem's peptide production capacity exceeded 20,000L by the end of the reporting period, supporting the demand for commercial production of solid-phase peptides[4]. - The company signed multiple commercial orders for GLP-1 peptides with domestic clients, indicating a strong market demand[4]. Other Financial Metrics - Interest income increased by 59.89% to approximately RMB 167.38 million, attributed to higher returns from fixed deposits[7]. - The company reported a decrease in investment income, which fell to ¥27.60 million from ¥108.55 million, a decline of 74.6% year-over-year[18]. - The company experienced a foreign exchange loss of ¥1.81 million in Q3 2024, contrasting with a gain of ¥9.86 million in Q3 2023[19]. - The company did not undergo an audit for the Q3 report[22]. - The report was released by the board of directors on October 29, 2024[22].